Abingdon Health FY revenues surge.

Lateral flow test manufacturer Abingdon Health said on Tuesday that full-year revenues had surged amid "strong commercial progress" across the group.

Abingdon Health
09 July 2024 10:10:48

Source: Sharecast

Abingdon said revenues were expected to be roughly 52% higher year-on-year at approximately £6.1m for the twelve months ended 30 June, with its contract development and manufacturing organisation unit being responsible for much of the revenue growth.

The AIM-listed group also anticipates that it will see "continued solid revenue growth" in FY25, which, along with "close management" of its operational cost base, will further drive operational profitability improvements.

Chief executive Chris Yates said: "Our key focus is to build a focused, high quality, sustainable, profitable business and we are making great strides towards this. We believe with our lateral flow focus, our comprehensive CDMO service proposition and growing self-test distribution platform that we are well placed to deliver further revenue growth in FY 2025 and beyond."

As of 1010 BST, Abingdon shares rallied 8.80% to 10.88p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.